1460880880-cf4975df-7147-4930-93d9-06670e86a857

1. A method of modulating Cl\u2212 secretion in a cell, comprising contacting a cell comprising a calcium-activated chloride channel (CaCC) with an effective amount of crofelemer.
2. The method of claim 1 wherein the CaCC is TMEM16A CaCC.
3. A The method of claim 1, wherein the cell further comprises one or more of a cystic fibrosis transmembrane conductance regulator (CFTR) and an epithelial sodium channel (ENaC).
4. A method of modulating Na+ secretion of a cell, comprising contacting a cell comprising a Na+ channel with an effective amount of crofelemer.
5. The method of claim 4 wherein the Na+ channel is epithelial sodium channel (ENaC).
6-32. (canceled)
33. The method of claim 1, wherein contacting the cell comprises contacting an intestinal cell or a bronchial cell.
34. The method of claim 1, wherein the effective amount of crofelemer is about 1-1,000 \u03bcM.
35. The method of claim 1, wherein the effective amount of crofelemer comprises from about 10 to about 2,000 mg of crofelemer.
36. The method of claim 4, wherein the effective amount of crofelemer comprises from about 10 to about 2,000 mg of crofelemer.
37. A method of treating a patient suffering from a calcium-activated chloride channel (CaCC) chanelpathy disorder comprising administering an effective amount of a pharmaceutical composition comprising crofelemer to the patient.
38. The method of claim 37, wherein the CaCC channelpathy disorder is selected from a group consisting of Cystic fibrosis, Erythromelalgia, Hyperkalemic periodic paralysis, Hypokalemic periodic paralysis, Long QT syndrome, Short QT syndrome, Malignant hyperthermia, Myotonia cogenita, and Neuromytonia.
39. The method of claim 37, wherein the pharmaceutical composition comprises from about 10 to about 2,000 mg crofelemer.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method of suppressing leakage from a body tissue, the method comprising the steps of:
providing a sleeve formed from an expandable material and having opposed open ends, the sleeve being dimensioned for constricting the body tissue to suppress flow of at least one of body fluid and air through the body tissue, and including an X ray opaque material visible under X ray fluoroscopy;
drawing the body tissue into the sleeve; and
constricting and collapsing the body tissue within the sleeve.
2. The method of claim 1, further comprising the step of resecting a portion of the body tissue by severing the sleeve between its opposed open ends after the drawing the body tissue into the sleeve step.
3. The method of claim 1, further comprising the step of confirming the collapse of the body tissue by fluoroscopically visualizing the X ray opaque material.
4. The method of claim 1, wherein the drawing the body tissue into the sleeve step comprises drawing a portion of a lung into the sleeve.
5. The method of claim 1, wherein the drawing the body tissue into the sleeve step is performed with vacuum assistance.
6. The method of claim 1, further comprising the step of expanding the sleeve prior to the drawing the body tissue into the sleeve step.
7. The method of claim 1, further comprising the step of confirming that the sleeve is in the desired position by viewing the sleeve fluoroscopically.
8. A method of suppressing fluid flow through a portion of a body organ, the method comprising the steps of:
providing a resilient elongate hollow sleeve, the sleeve having at least a portion thereof configured to be viewable through an external imaging technique;
expanding the sleeve to an expanded configuration;
drawing a portion of the body organ into the expanded sleeve;
releasing the sleeve from its expanded configuration such that the sleeve collapses the portion of the body organ disposed therein.
9. The method of claim 8, further comprising the step of confirming that there is substantially no fluid flow through the portion of the body organ disposed within the sleeve.
10. The method of claim 8, further comprising the step of verifying the placement of the sleeve through X ray fluoroscopy.
11. The method of claim 8, further comprising the step of resecting a portion of the body organ by severing the sleeve and the body organ disposed therein.
12. The method of claim 8, wherein the drawing a portion of the body organ in the expanded sleeve step is performed with vacuum assistance.
13. The method of claim 8, wherein the drawing a portion of the body organ into the expanded sleeve step comprises drawing a portion of a lung into the expanded sleeve.
14. The method of claim 8, wherein the expanding the sleeve step is performed with vacuum assistance.
15. The method of claim 8, wherein the providing a resilient hollow sleeve step comprises providing a resilient hollow sleeve containing radiopaque material.
16. The method of claim 15, wherein the providing a resilient hollow sleeve step comprises providing a resilient hollow sleeve containing radiopaque spheres embedded into the sleeve.
17. The method of claim 15, wherein the providitig a resilient hollow sleeve step comprises providing a resilient hollow sleeve containing radiopaque strips.
18. The method of claim 8, further comprising the step of securing the sleeve onto the body organ.
19. The method of claim 15, wherein the step of securing the sleeve onto the body organ is performed by inwardly facing projections on the sleeve.
20. The method of claim 19, wherein the step of securing the sleeve onto the body organ takes place automatically as the sleeve is released from its expanded configuration.